1
|
Laidi C, Hajek T, Spaniel F, Kolenic M, d'Albis MA, Sarrazin S, Mangin JF, Duchesnay E, Brambilla P, Wessa M, Linke J, Polosan M, Favre P, Versace AL, Phillips ML, Manjon JV, Romero JE, Hozer F, Leboyer M, Coupe P, Houenou J. Cerebellar parcellation in schizophrenia and bipolar disorder. Acta Psychiatr Scand 2019; 140:468-476. [PMID: 31418816 DOI: 10.1111/acps.13087] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 08/12/2019] [Indexed: 12/11/2022]
Abstract
OBJECTIVE The cerebellum is involved in cognitive processing and emotion control. Cerebellar alterations could explain symptoms of schizophrenia spectrum disorder (SZ) and bipolar disorder (BD). In addition, literature suggests that lithium might influence cerebellar anatomy. Our aim was to study cerebellar anatomy in SZ and BD, and investigate the effect of lithium. METHODS Participants from 7 centers worldwide underwent a 3T MRI. We included 182 patients with SZ, 144 patients with BD, and 322 controls. We automatically segmented the cerebellum using the CERES pipeline. All outputs were visually inspected. RESULTS Patients with SZ showed a smaller global cerebellar gray matter volume compared to controls, with most of the changes located to the cognitive part of the cerebellum (Crus II and lobule VIIb). This decrease was present in the subgroup of patients with recent-onset SZ. We did not find any alterations in the cerebellum in patients with BD. However, patients medicated with lithium had a larger size of the anterior cerebellum, compared to patients not treated with lithium. CONCLUSION Our multicenter study supports a distinct pattern of cerebellar alterations in SZ and BD.
Collapse
Affiliation(s)
- C Laidi
- Institut National de la Santé et de la Recherche Médicale (INSERM), U955 - Translational Psychiatry, Institut Mondor de Recherche Biomédicale, Psychiatrie, Créteil, France.,Pôle de Psychiatrie, Assistance Publique-Hôpitaux de Paris (AP-HP), Faculté de Médecine de Créteil, DHU PePsy, Hôpitaux Universitaires Mondor, Créteil, France.,Fondation Fondamental, Créteil, France.,NeuroSpin, CEA, Paris Saclay University, Gif-sur-Yvette, France
| | - T Hajek
- Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.,National Institute of Mental Health, Klecany, Czech Republic
| | - F Spaniel
- National Institute of Mental Health, Klecany, Czech Republic
| | - M Kolenic
- National Institute of Mental Health, Klecany, Czech Republic
| | - M-A d'Albis
- Institut National de la Santé et de la Recherche Médicale (INSERM), U955 - Translational Psychiatry, Institut Mondor de Recherche Biomédicale, Psychiatrie, Créteil, France.,Pôle de Psychiatrie, Assistance Publique-Hôpitaux de Paris (AP-HP), Faculté de Médecine de Créteil, DHU PePsy, Hôpitaux Universitaires Mondor, Créteil, France.,Fondation Fondamental, Créteil, France.,NeuroSpin, CEA, Paris Saclay University, Gif-sur-Yvette, France
| | - S Sarrazin
- Institut National de la Santé et de la Recherche Médicale (INSERM), U955 - Translational Psychiatry, Institut Mondor de Recherche Biomédicale, Psychiatrie, Créteil, France.,NeuroSpin, CEA, Paris Saclay University, Gif-sur-Yvette, France
| | - J-F Mangin
- NeuroSpin, CEA, Paris Saclay University, Gif-sur-Yvette, France
| | - E Duchesnay
- NeuroSpin, CEA, Paris Saclay University, Gif-sur-Yvette, France
| | - P Brambilla
- Department of Neurosciences and Mental Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - M Wessa
- Department of Clinical Psychology and Neuropsychology, Johannes Gutenberg-University, Mainz, Germany
| | - J Linke
- Department of Clinical Psychology and Neuropsychology, Johannes Gutenberg-University, Mainz, Germany
| | - M Polosan
- Grenoble Institute of Neuroscience, INSERM U1216, Hôpital Grenoble Alpes, Grenoble Alpes University, Grenoble, France
| | - P Favre
- Institut National de la Santé et de la Recherche Médicale (INSERM), U955 - Translational Psychiatry, Institut Mondor de Recherche Biomédicale, Psychiatrie, Créteil, France.,Fondation Fondamental, Créteil, France.,NeuroSpin, CEA, Paris Saclay University, Gif-sur-Yvette, France
| | - A L Versace
- Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh, Pittsburgh, PA, USA
| | - M L Phillips
- Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh, Pittsburgh, PA, USA
| | - J V Manjon
- Instituto Universitario de Tecnologías de la Información y Comunicaciones (ITACA), Universitat Politècnica de València, Valencia, España
| | - J E Romero
- Instituto Universitario de Tecnologías de la Información y Comunicaciones (ITACA), Universitat Politècnica de València, Valencia, España
| | - F Hozer
- Department of Psychiatry, Assistance Publique-Hôpitaux de Paris (AP-HP) - Hôpital Corentin Celton, Paris Descartes University, Près Sorbonne Paris Cité, Issy-les- Moulineaux, France
| | - M Leboyer
- Institut National de la Santé et de la Recherche Médicale (INSERM), U955 - Translational Psychiatry, Institut Mondor de Recherche Biomédicale, Psychiatrie, Créteil, France.,Pôle de Psychiatrie, Assistance Publique-Hôpitaux de Paris (AP-HP), Faculté de Médecine de Créteil, DHU PePsy, Hôpitaux Universitaires Mondor, Créteil, France.,Fondation Fondamental, Créteil, France.,NeuroSpin, CEA, Paris Saclay University, Gif-sur-Yvette, France
| | - P Coupe
- Pictura Research Group, Unité Mixte de Recherche Centre National de la Recherche Scientifique (UMR 5800), Laboratoire Bordelais de Recherche en Informatique, Centre National de la Recherche Scientifique, Talence, France.,Pictura Research Group, Unité Mixte de Recherche Centre National de la Recherche Scientifique (UMR 5800), Laboratoire Bordelais de Recherche en Informatique, University Bordeaux, Talence, France
| | - J Houenou
- Institut National de la Santé et de la Recherche Médicale (INSERM), U955 - Translational Psychiatry, Institut Mondor de Recherche Biomédicale, Psychiatrie, Créteil, France.,Pôle de Psychiatrie, Assistance Publique-Hôpitaux de Paris (AP-HP), Faculté de Médecine de Créteil, DHU PePsy, Hôpitaux Universitaires Mondor, Créteil, France.,Fondation Fondamental, Créteil, France.,NeuroSpin, CEA, Paris Saclay University, Gif-sur-Yvette, France
| |
Collapse
|
3
|
Colle R, de Larminat D, Rotenberg S, Hozer F, Hardy P, Verstuyft C, Fève B, Corruble E. PPAR-γ Agonists for the Treatment of Major Depression: A Review. Pharmacopsychiatry 2016; 50:49-55. [PMID: 27978584 DOI: 10.1055/s-0042-120120] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Introduction: Selective agonists of the nuclear transcription factor peroxisome proliferator-activated receptor-gamma (PPAR-γ) are used for the treatment of type 2 diabetes. We reviewed their efficacy and safety for the treatment of major depression and the association of their potential antidepressant effects with changes in biomarkers of metabolism and inflammation. Methods: From 8 studies, 4 open-label trials, and 4 randomized controlled trials (RCT) (3 vs. placebo and 1 vs. metformin), 448 patients with major depression were included, of which 209 patients received PPAR-γ agonists (pioglitazone or rosiglitazone) for 6-12 weeks, either alone or in add-on therapy to conventional treatments. Results: PPAR-γ agonists have antidepressant effects in the 4 open-label studies and in 3 out of 4 RCT. No major adverse event was reported. Improvement in depression scores was associated with improvement in 3 biomarkers of insulin resistance (homeostatic model assessment [HOMA-IR], oral glucose tolerance test, and fasting plasma glucose) and 1 biomarker of inflammation (interleukin-6) among 21 biomarkers studied. Conclusion: PPAR-γ agonists may have antidepressant properties, which need to be assessed in further studies of major depressive episodes.
Collapse
Affiliation(s)
- R Colle
- University Paris-Sud, Le Kremlin Bicêtre, France
| | | | - S Rotenberg
- University Paris-Sud, Le Kremlin Bicêtre, France
| | - F Hozer
- University Paris-Sud, Le Kremlin Bicêtre, France
| | - P Hardy
- University Paris-Sud, Le Kremlin Bicêtre, France
| | - C Verstuyft
- University Paris-Sud, Le Kremlin Bicêtre, France
| | - B Fève
- Sorbonne Universités, Université Pierre et Marie Curie, Centre de Recherche Saint-Antoine, INSERM UMR_S938, Paris, France
| | - E Corruble
- University Paris-Sud, Le Kremlin Bicêtre, France
| |
Collapse
|